Bibliography: Substance-Related and Addictive Disorders
This section contains a compilation of recent publications that have shaped the thinking in the field as well as classic works that remain important to the subject reviewed in this issue. This bibliography has been compiled by experts in the field and members of the editorial and advisory boards. Entries are listed chronologically and within topics and years by first author. Articles from the bibliography that are reprinted in this issue are in bold type.
Substance-Related Disorders
Volkow ND, Baler RD: Addiction science: uncovering neurobiological complexity. Neuropharmacology 2014 Jan;76 Pt B:235–249
Belcher AM, Volkow ND, Moeller FG, et al: Personality traits and vulnerability or resilience to substance use disorders. Trends Cogn Sci 2014; 18:211–217
Chiesa A, Serretti A: Are mindfulness-based interventions effective for substance use disorders? A systematic review of the evidence. Subst Use Misuse 2014; 49:492–512
Everitt BJ: Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories—indications for novel treatments of addiction. Eur J Neurosci 2014; 40:2163–2182
Wise RA, Koob GF: The development and maintenance of drug addiction. Neuropsychopharmacology 2014; 39:254–262
Pettinati HM, O’Brien CP, Dundon WD: Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry 2013; 170:23–30
Volkow ND, Wang GJ, Tomasi D, et al: The addictive dimensionality of obesity. Biol Psychiatry 2013; 73:811–818
Volkow ND, Wang GJ, Fowler JS, et al: Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 2012; 52:321–336
Koob GF, Volkow ND: Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35:217–238
Opioids and Pain
Soyka M: New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil 2015; 6:1–14
Fullerton CA, Kim M, Thomas CP, et al: Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv 2014; 65:146–157
Mattick RP, Breen C, Kimber J, et al: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2:CD002207
Nuckols TK, Anderson L, Popescu I, et al: Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med 2014; 160:38–47
Thomas CP, Fullerton CA, Kim M, et al: Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv 2014; 65:158–170
Centers for Disease Control and Prevention: Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011; 60:1487–1492
Institute of Medicine Committee on Advancing Pain Research Care and Education: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC, National Academies Press, 2011
Turk DC, Wilson HD, Cahana A: Treatment of chronic non-cancer pain. Lancet 2011; 377:2226–2235
Stotts AL, Dodrill CL, Kosten TR: Opioid dependence treatment: options in pharmacotherapy. Expert Opin Pharmacother 2009; 10:1727–1740
Cannabis
Volkow ND, Baler RD, Compton WM, et al: Adverse health effects of marijuana use. N Engl J Med 2014; 370:2219–2227
Pertwee RG: Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci 2012; 367:3353–3363
Fraser GA: The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther 2009; 15:84–88
Leweke FM, Giuffrida A, Koethe D, et al: Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007; 94:29–36
Kathuria S, Gaetani S, Fegley D, et al: Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9:76–81
Piomelli D: The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4:873–884
Stimulants
Ilieva IP, Hook CJ, Farah MJ: Prescription stimulants' effects on healthy inhibitory control, working memory, and episodic memory: a meta-analysis. J Cogn Neurosci 2015; 27:1069–1089
Coghill DR, Seth S, Pedroso S, et al: Effects of methylphenidate on cognitive functions in children and adolescents with attention-deficit/hyperactivity disorder: evidence from a systematic review and a meta-analysis. Biol Psychiatry 2014; 76:603–615
Franke AG, Bagusat C, Rust S, et al: Substances used and prevalence rates of pharmacological cognitive enhancement among healthy subjects. Eur Arch Psychiatry Clin Neurosci 2014; 264(Suppl 1):S83–S90
Kosten TR, Domingo CB, Shorter D, et al: Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend 2014; 140:42–47
Kosten TR, Wu G, Huang W, et al: Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol Psychiatry 2013; 73:219–224
Morente-Sánchez J, Zabala M: Doping in sport: a review of elite athletes’ attitudes, beliefs, and knowledge. Sports Med 2013; 43:395–411
Weyandt LL, Marraccini ME, Gudmundsdottir BG, et al: Misuse of prescription stimulants among college students: a review of the literature and implications for morphological and cognitive effects on brain functioning. Exp Clin Psychopharmacol 2013; 21:385–407
Boghosian T, Mazzoni I, Barroso O, et al: Investigating the use of stimulants in out-of-competition sport samples. J Anal Toxicol 2011; 35:613–616
Sahakian BJ, Morein-Zamir S: Neuroethical issues in cognitive enhancement. J Psychopharmacol 2011; 25:197–204
Tobacco
Cavazos-Rehg PA, Breslau N, Hatsukami D, et al: Smoking cessation is associated with lower rates of mood/anxiety and alcohol use disorders. Psychol Med 2014; 44:2523–2535
Prochaska JJ, Hall SE, Delucchi K, et al: Efficacy of initiating tobacco dependence treatment in inpatient psychiatry: a randomized controlled trial. Am J Public Health 2014; 104:1557–1565
Shahab L, Andrew S, West R: Changes in prevalence of depression and anxiety following smoking cessation: results from an international cohort study (ATTEMPT). Psychol Med 2014; 44:127–141
Taylor G, McNeill A, Girling A, et al: Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ 2014; 348:g1151
Khaled SM, Bulloch AG, Williams JV, et al: Persistent heavy smoking as risk factor for major depression (MD) incidence—evidence from a longitudinal Canadian cohort of the National Population Health Survey. J Psychiatr Res 2012; 46:436–443
McFall M, Saxon AJ, Malte CA, et al; CSP 519 Study Team: Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA 2010; 304:2485–2493
Ziedonis D, Hitsman B, Beckham JC, et al: Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 2008; 10:1691–1715
Alcohol
Day E, Copello A, Hull M: Assessment and management of alcohol use disorders. BMJ 2015; 350:h715
Koob GF: Alcohol use disorders: tracts, twins, and trajectories. Am J Psychiatry 2015; 172:499–501
O’Brien C: In treating alcohol use disorders, why not use evidence-based treatment? Am J Psychiatry 2015; 172:305–306
Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism: Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD, Substance Abuse and Mental Health Services Administration, 2015
Enoch MA: Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. Pharmacol Biochem Behav 2014; 123:17–24
Galanter M: Alcoholics Anonymous and twelve-step recovery: a model based on social and cognitive neuroscience. Am J Addict 2014; 23:300–307
Gelernter J, Kranzler HR, Sherva R, et al: Genome-wide association study of alcohol dependence: significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry 2014; 19:41–49
Jonas DE, Amick HR, Feltner C, et al: Pharmacotherapy for Adults with Alcohol-Use Disorders in Outpatient Settings. Comparative Effectiveness Review No. 134. AHRQ Publication No. 14-EHC029-EF. Rockville, MD, Agency for Healthcare Research and Quality, 2014. Available at effectivehealthcare.ahrq.gov/ehc/products/477/1908/alcohol-misuse-drug-therapy-report-140513.pdf
Klimas J, Tobin H, Field CA, et al: Psychosocial interventions to reduce alcohol consumption in concurrent problem alcohol and illicit drug users. Cochrane Database Syst Rev 2014; 12:CD009269
Lenaerts E, Matheï C, Matthys F, et al: Continuing care for patients with alcohol use disorders: a systematic review. Drug Alcohol Depend 2014; 135:9–21
Maisel NC, Blodgett JC, Wilbourne PL, et al: Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013; 108:275–293
Information & Authors
Information
Published In
History
Published in print: Summer 2015
Published online: 14 July 2015
Authors
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).